The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure ...

The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.

Frailty and accelerated aging are common in pulmonary hypertension, with frailty an independent risk factor for early death.